The anti-C5a antibody vilobelimab efficiently inhibits C5a in patients with severe COVID-19.
Vlaar APJ, Lim EHT, de Bruin S, Rückinger S, Pilz K, Brouwer MC, Guo RF, Heunks LMA, Busch MH, van Paassen P, Riedemann NC, van de Beek D.
Vlaar APJ, et al. Among authors: van paassen p, van de beek d, de bruin s.
Clin Transl Sci. 2022 Apr;15(4):854-858. doi: 10.1111/cts.13213. Epub 2022 Jan 14.
Clin Transl Sci. 2022.
PMID: 35029045
Free PMC article.